| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 05/16/2002 | WO2001087335A3 Method for selectively inhibiting ghrelin action |
| 05/16/2002 | WO2001076638A3 Compositions for drug delivery |
| 05/16/2002 | WO2001058434A3 Diagnostic and therapeutic compositions and methods for affecting tumor growth using oxygen mimetic agents |
| 05/16/2002 | US20020058853 Method of administering a therapeutically active substance |
| 05/16/2002 | US20020058615 Endothelial specific targeting |
| 05/16/2002 | US20020058057 Brachytherapy seed |
| 05/16/2002 | US20020058028 Method of in situ diagnosis by spectroscopic analysis of biological stain compositions |
| 05/16/2002 | US20020058008 Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| 05/16/2002 | DE10117242C1 New dimeric tetraazacyclododecane derivatives and their metal complexes useful as components of diagnostic agents, especially X-ray contrast agents, and radiotherapeutics |
| 05/16/2002 | CA2429127A1 In vivo detection of biomolecule concentrations using fluorescent tags |
| 05/16/2002 | CA2425829A1 Proteases |
| 05/15/2002 | EP1204683A1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 05/15/2002 | EP1204430A2 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes |
| 05/15/2002 | EP1096941A4 Bone marrow cells as a source of neurons for brain and spinal cord repair |
| 05/15/2002 | CN1084632C Process for purification of opacifying contrast agents |
| 05/15/2002 | CN1084595C Utilizations of edible oil |
| 05/14/2002 | US6388061 Includes ruthenium tris(bipyridyl) label bonded to the nitrogen base |
| 05/14/2002 | US6387629 Use of cathepsin S in the diagnosis and treatment of endometriosis |
| 05/14/2002 | US6387350 Utilizing a labeled single chain antibody fragment or subfragment with a molecular weight of 85,000 daltons or less that specifically binds to an antigen produced by or associated with tumors or lesions |
| 05/14/2002 | CA2214829C Methods and compositions for in-vivo detection of oral cancers and precancerous conditions |
| 05/10/2002 | WO2002037088A1 Material which is provided with an nmr contrast agent and method for producing the same |
| 05/10/2002 | WO2002036784A1 Transgenic animals for analysing cyp3a4 cytochrome p450 gene regulation |
| 05/10/2002 | WO2002036161A2 Novel targeted compositions for diagnostic and therapeutic use |
| 05/10/2002 | WO2002036078A2 Targeting pluripotent stem cells to tissues |
| 05/10/2002 | WO2002036069A2 Hypotension |
| 05/10/2002 | WO2001082976A3 Functional mri agents for cancer imaging |
| 05/10/2002 | WO2001064031A3 Slpi knockout mice and methods for wound treatment |
| 05/10/2002 | WO2001005388A3 Use of a fatty derivative for the treatment of external secretiondisorders |
| 05/10/2002 | WO2001000246A3 Hydrogels derived from chitosan and poly(ethylene glycol) |
| 05/10/2002 | CA2428606A1 Novel targeted compositions for diagnostic and therapeutic use |
| 05/09/2002 | US20020056146 Expression vector for use in generation of trangenic animals; for use in animal modeling of disease |
| 05/09/2002 | US20020056144 Transgenic animal models for cardiac hypertrophy and methods of use thereof (screening) |
| 05/09/2002 | US20020055681 Ultrasonic image persistence using contrast agents |
| 05/09/2002 | US20020054871 Treating a host suffering from hyperlipidemia resulting from elevated levels of at least one of very low density lipoproteins and triglycerides and effective amount of an agent that reduces the level of active apolipoprotein E |
| 05/09/2002 | US20020054854 Stabilized microbubble compositions |
| 05/09/2002 | US20020054852 A carrier material reflects or absorbs or emits electromagnetic or mechanical vibration enabling the monitoring of carrier material and a drug associated with carrier, and a targeting agent bind to the site |
| 05/08/2002 | EP1203944A1 Tumor cell identification apparatus and tumor cell identification method |
| 05/08/2002 | EP1203026A1 Binding moieties for fibrin |
| 05/08/2002 | EP1202671A1 Microparticles useful as ultrasonic contrast agents and for lymphatic system |
| 05/08/2002 | EP1202670A1 Hollow microspheres with controlled fragility for medical use |
| 05/08/2002 | EP0971677A4 Bone cement and method of preparation |
| 05/08/2002 | EP0789783B1 Antigen binding peptides (abtides) from peptide libraries |
| 05/08/2002 | EP0736056B1 Cascade polymers with iodine aromatic compounds |
| 05/08/2002 | EP0629240B1 Altered antibodies, products and processes relating thereto |
| 05/08/2002 | CN1348362A Magnetically responsive composition |
| 05/07/2002 | US6384195 Produced by partitioning method; therapeutics |
| 05/07/2002 | US6383767 Luminescent in vivo glucose measurement |
| 05/07/2002 | US6383470 Wall material consists of a copolymer made of a synthetic polymeric material and a biopolymer to which site-specific, structure-specific or tissue-specific substances are bound; use in treatment ultrasonic diagnosis |
| 05/07/2002 | CA2250167C Cryogenic accumulator for spin-polarized xenon-129 |
| 05/02/2002 | WO2002034297A2 Endoscopic vascular visualisation, diagnostic and/or surgical procedure |
| 05/02/2002 | WO2002034295A1 Synthetic regulatory compounds |
| 05/02/2002 | WO2001089584A3 Contrast agents |
| 05/02/2002 | WO2001082795A3 Magnetic resonance imaging agents for the delivery of therapeutic agents |
| 05/02/2002 | WO2001069244A3 Method for labeling individual cells |
| 05/02/2002 | WO2001036617A3 Assay for measuring enzyme activity in vivo |
| 05/02/2002 | US20020052594 Method and kit for imaging and treating organs and tissues |
| 05/02/2002 | US20020052560 Process for determining the functional residual capacity of the lungs |
| 05/02/2002 | US20020052477 Fibroblast growth factor homologous factor-1 (fhf-1) and methods of use |
| 05/02/2002 | US20020052358 Methods and compositions related to modulators of annexin and cartilage homeostasis |
| 05/02/2002 | US20020052315 Conformationally constrained backbone cyclized somatostatin analogs |
| 05/02/2002 | US20020052311 Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| 05/02/2002 | US20020052033 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 05/02/2002 | US20020051750 Osmotically stabilized microbubble preparations |
| 05/02/2002 | US20020051712 UHV compatible lead through, device and procedure for highly effective production of nuclear spin polarized 3He at high polarization |
| 05/02/2002 | EP1200137A1 Agent for occluding blood vessels |
| 05/02/2002 | EP1200134A1 Porous inorganic targeted ultrasound contrast agents |
| 05/02/2002 | EP0833669B1 Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients |
| 05/01/2002 | CN1346628A Antimicrobial caries detecting composition |
| 04/30/2002 | US6380169 Metal complex containing oligonucleoside cleavage compounds and therapies |
| 04/30/2002 | US6379955 Optical fiberless sensors |
| 04/30/2002 | US6379671 Using a polypeptide antigen mixture |
| 04/30/2002 | US6379647 Use of mononuclear phagocytes in in vivo imaging of hypoxic/ischaemic tissue |
| 04/30/2002 | US6378526 Methods of ophthalmic administration |
| 04/30/2002 | CA2053478C Magnetic resonance imaging agent |
| 04/30/2002 | CA2020247C Antibodies reactive with human carcinomas |
| 04/25/2002 | WO2002032860A2 Dynamic organ function monitoring agents |
| 04/25/2002 | WO2002032466A1 Light sensitive compounds for instant determination of organ function |
| 04/25/2002 | WO2002032465A1 Tissue-specific exogenous optical agents |
| 04/25/2002 | WO2002032464A1 Novel dyes for organ function monitoring |
| 04/25/2002 | WO2002032421A1 Indole compounds as minimally physiologial function monitioring agents |
| 04/25/2002 | WO2002032375A2 Uses of monoclonal antibody 8h9 |
| 04/25/2002 | WO2002032292A2 Methods for development and use of diagnostic and therapeutic agents |
| 04/25/2002 | WO2002032285A2 Hydrophilic light absorbing compositions for determination of physiological function in critically ill patients |
| 04/25/2002 | US20020049986 High throughput genetic screening of lipid and cholesterol processing using fluorescent compounds |
| 04/25/2002 | US20020049308 Novel macrocyclic magnetic resonance imaging contrast agents |
| 04/25/2002 | US20020048777 Nucleotide sequences for use in therapy, monitoring and screning preferential tumors |
| 04/25/2002 | US20020048598 Branched polymeric structure which provides a structural support for a mono-layer, bi-layer or multi-layered lipid coating. |
| 04/25/2002 | US20020048582 Methods of modulating angiogenesis |
| 04/25/2002 | DE10050114A1 Verwendung einer Gelmasse Using a gel mass |
| 04/25/2002 | DE10046514A1 Verfahren zur bildlichen Darstellung und Diagnose von Thromben mittels Kernspintomographie unter Verwendung partikulärer Kontrastmittel Method for imaging and diagnosis of thrombi by magnetic resonance imaging using particulate contrast agent |
| 04/25/2002 | CA2425718A1 Dynamic organ function monitoring agents |
| 04/25/2002 | CA2425705A1 Light sensitive compounds for instant determination of organ function |
| 04/25/2002 | CA2425701A1 Indole compounds as minimally physiologial function monitioring agents |
| 04/25/2002 | CA2425698A1 Hydrophilic light absorbing compositions for determination of physiological function in critically ill patients |
| 04/25/2002 | CA2423843A1 Uses of monoclonal antibody 8h9 |
| 04/24/2002 | EP1199566A1 Methods of screening affinity marker libraries |
| 04/24/2002 | EP1198256A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 04/24/2002 | EP1198255A1 Identification of compounds that modify transcriptional responses to hypoxia |
| 04/24/2002 | EP1198254A2 Carrier-drug conjugate |
| 04/24/2002 | EP1181939A9 Method for evaluating matrix metalloprotease inhibitory activity |